At CSL, we recognise that responsible management and efficient use of natural resources is a key to our sustainable growth and our ability to enable efficient and reliable supply of our life-saving medicines. We believe this makes us a stronger, more resilient business better prepared to navigate the future.
In 2022, we announced enterprise emissions reduction targets. In alignment with the Science-Based Targets initiative (SBTi). At the end of May 2025, the SBTi approved CSL’s near-term science-based emissions reduction targets. These are:
CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030 (from a FY2021 base year)1.
CSL commits that 73.1% of CSL’s suppliers by emissions – covering Scope 3 categories: purchased goods and services, capital goods, upstream transportation and distribution, business travel, and downstream transportation and distribution – will have science-based targets by FY2030.
1 In 2022, CSL announced its initial target to reduce emissions associated with its own operations by 40%. This target has since been updated to 42% to align with the SBTi’s reporting period for calendar years. CSL’s Scope 3-related target, approved by the SBTi (as outlined above), is part of CSL’s broader intention to engage suppliers who account for 67% of all CSL’s total Scope 3 emissions. CSL aims for these suppliers to have Scope 1 and 2 emissions reduction targets aligned* with the SBTi. This broader intention applies to suppliers across all Scope 3 categories.
The target boundary includes land-related emissions and removals from bioenergy feedstocks.
* Either the supplier has SBTi-validated targets, or CSL has conducted due diligence to confirm that the supplier’s targets meet SBTi criteria.
